J F Arevalo

Summary

Publications

  1. request reprint
    Arevalo J, Wu L, Sanchez J, Maia M, Saravia M, Fernandez C, et al. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye (Lond). 2009;23:117-23 pubmed
    ..To study the effects of intravitreal bevacizumab (Avastin) on retinal neovascularization (RN) in patients with proliferative diabetic retinopathy (PDR)...
  2. Arevalo J, Sanchez J, Wu L, Maia M, Alezzandrini A, Brito M, et al. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology. 2009;116:1488-97, 1497.e1 pubmed publisher
    ..San Francisco, CA; 1.25 or 2.5 mg) in patients with diffuse diabetic macular edema (DDME). In addition, a comparison of the 2 different doses of intravitreal bevacizumab (IVB) used is presented...

Detail Information

Publications2

  1. request reprint
    Arevalo J, Wu L, Sanchez J, Maia M, Saravia M, Fernandez C, et al. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye (Lond). 2009;23:117-23 pubmed
    ..To study the effects of intravitreal bevacizumab (Avastin) on retinal neovascularization (RN) in patients with proliferative diabetic retinopathy (PDR)...
  2. Arevalo J, Sanchez J, Wu L, Maia M, Alezzandrini A, Brito M, et al. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology. 2009;116:1488-97, 1497.e1 pubmed publisher
    ..San Francisco, CA; 1.25 or 2.5 mg) in patients with diffuse diabetic macular edema (DDME). In addition, a comparison of the 2 different doses of intravitreal bevacizumab (IVB) used is presented...